By Michael Erman SAN FRANCISCO, Jan 12 (Reuters) - Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug ...

Pfizer’s stake in ViiV Healthcare will be taken over by Shiongi, another minority shareholder in the HIV medicines company.

Pfizer is acquiring Metsera, a clinical-stage biopharmaceutical company with a focus on medicines for obesity and cardiometabolic diseases, in a deal valued at up to $7.3 billion. “Pfizer said it ...

President Donald Trump announced an agreement with Pfizer to voluntarily sell its medications at lower prices in the U.S., as his administration pushes to link the nation's drug prices to cheaper ...

Pfizer is one of the world's largest pharmaceutical companies. Even after losing more than half of its value, it still has a ...

Pfizer's been focusing on a hot area of healthcare recently: GLP-1 drugs.

(Reuters) - Pfizer filed an antitrust lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for biotech Metsera to stall, not close, the deal, a tactic it said is ...

Pfizer's (NYSE:PFE) entry into the obesity treatment market through its $4.9B deal to acquire Metsera (NASDAQ:MTSR) is the latest indication that Big Pharma wants a piece of the weight loss drugs pie ...

Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, despite near-term headwinds. PFE maintains strong free cash flow and improved ...

The Trump administration and Pfizer PFE announced an agreement on Sept. 30 that includes most-favored-nation pricing for Pfizer’s drugs in Medicaid programs, discounts for direct sales of Pfizer drugs ...

President Trump, during an Oval Office event Tuesday, called out Albert Bourla, the CEO of Pfizer, for overcharging Americans for prescription drugs. "The United States has just 4% of the world’s ...